Accelerated delivery of transcranial magnetic stimulation is safe and effective

(Press-News.org) May 12, 2023 — Accelerated schedules for repetitive transcranial magnetic stimulation (rTMS) can be offered to patients experiencing treatment-resistant major depressive disorder (MDD), a group of clinician–researchers and neuroscientists have concluded. The group cautions that such treatment should be proposed only after detailed discussion with patients about acceleration being an alternate form of rTMS scheduling, with documentation of informed consent.

The recommendations are published in a special issue of Harvard Review of Psychiatry (HRP), “Interventional Neuropsychiatry and Neuromodulation: An Emerging Subspecialty in Brain Medicine.” HRP is published in the Lippincott portfolio by Wolters Kluwer.

Repetitive TMS is a noninvasive therapy in which an electromagnet delivers repeated low-intensity pulses to stimulate the brain. It has been proven safe and effective in numerous clinical trials involving patients whose MDD does not respond to antidepressant medication. Conventionally, rTMS is given once daily 20 to 30 days over four to six weeks. That places great time demands on both patients and clinicians.

Theta burst stimulation treats MDD

The next step in development of rTMS is accelerated schedules in which patients undergo two or more sessions per day, each approximately 30 minutes long, separated by one hour or more. Although this change was just as effective in treating depression as once-daily rTMS, it created a different kind of impracticality and clinical inefficiency, according to Leo Chen, MBBS, MPsych, PhD, FRANZCP, of Monash University/Alfred Health in Melbourne, Australia, and colleagues. “These schedules required patients to attend treatment settings for long periods on each treatment day, limiting patient capacity at treatment clinics,” they note.

The time burden can be alleviated, at least in part, with a novel approach called theta-burst stimulation (TBS). The most commonly used conventional rTMS protocol delivers electromagnetic pulses at a frequency of 10 Hz, whereas TBS refers to three pulses applied at 50 Hz (gamma frequency), repeated at 5 Hz (theta frequency) intervals. Two or more TBS sessions can be delivered within an hour.

Dr. Chen and his colleagues recently published results from a multicenter randomized, controlled trial in which 10 days of TBS was compared head-to-head with a four week course of conventional rTMS. The two approaches were similar in antidepressant effect and safety. This was the largest study of accelerated TBS in depression to date.

Standardization needed

Accelerated delivery doesn’t necessarily mean accelerated response, the authors caution. Some retrospective studies have shown twice-daily rTMS induces antidepressant effects faster than once-daily administration, but the evidence is mixed. One barrier is that studies have varied widely in factors such as the stimulation target, frequency and intensity of stimulation, the duration of breaks between sessions, and the number of pulses applied per session and over a treatment course.

Importantly, though, “accelerated rTMS’s antidepressant efficacy appears comparable to conventional, once-daily rTMS protocols,” Dr. Chen’s group writes. In addition, “studies show that accelerated rTMS protocols are well-tolerated and not associated with serious adverse effects.”

“As with all therapies, the efficacy, safety, and tolerability of protocols that deviate from those investigated in clinical trials are unknown and should be cautioned against,” the researchers continue. “The durability and depression relapse patterns following accelerated rTMS remain a recognized knowledge gap.”

Read [Accelerated Repetitive Transcranial Magnetic Stimulation to Treat Major Depression: The Past, Present, and Future]

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

###

About HRP

Harvard Review of Psychiatry is the authoritative source for scholarly reviews and perspectives on a diverse range of important topics in psychiatry. Founded by the Harvard Medical School Department of Psychiatry, the journal is peer-reviewed and not industry sponsored. It is the property of President and Fellows of Harvard College and is affiliated with all of the Departments of Psychiatry at the Harvard teaching hospitals.

Articles encompass all major issues in contemporary psychiatry, including (but not limited to) neuroscience, psychopharmacology, psychotherapy, history of psychiatry, and ethics. In addition to scholarly reviews, perspectives articles, and columns, the journal includes a Clinical Challenge section that presents a case followed by discussion and debate from a panel of experts.

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.

Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

END